reports
- Jacob Mekhael
MaaT Pharma 1H24 update extends runway into 2Q25, MaaT013 phase 3 topl...
MaaT reported 1H24 results, which come with an extension of the company's cash runway into 2Q25 (from 1Q25) through prioritisation of resources on the key programs for MaaT013 and MaaT033, while management confirmed they are exploring all options for additional funding. In addition, the company reiterates the timeline for the topline results from the phase 3 (ARES) trial of MaaT013 in aGvHD in Europe, which continue to be expected in mid-4Q24 – we view this as an important trigger for the compan...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Wim Lewi
MaaT Pharma publie ses résultats semestriels 2024 et réalise un point ...
Lyon, France--(BUSINESS WIRE)-- Regulatory news: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd’hui la publication de ses résultats financiers semestriels pour une période de 6 mois clôturée au 30 juin 2024 et réalise un point sur ses activités. « Forts des données positives présentées en avril 2024 lors du congrès de l'EBMT pour MaaT013 et du succès de not...
MaaT Pharma Publishes its Half Year 2024 Results and Provides a Busine...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced its half year financial results for the six-month period ended June 30, 2024, and provided a business overview. “Building on the positive data for MaaT013 in April 2024 presented at the EBMT Congress, and the success of our recent fundraising, we have dedicated the first half of 2024 to pursuing recr...
- ING Helpdesk
MaaT Pharma: Information mensuelle relative au nombre total de droits ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 31 août 2024. Place de cotation : Euronext Paris Code ISIN : FR0012634822 Site web : Date Nombre total d’actions composant le capital social ...
MaaT Pharma annonce sa participation à des conférences investisseurs e...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem Therapies™ (MET)1 visant à améliorer la survie des patients atteints de cancers, annonce la présentation de deux posters lors du Congrès annuel de la « Society of Hematologic Oncology » qui se tiendra du 4 au 7 septembre 2024 à Houston, Texas aux États-Unis. MaaT Pharma annonce également que des membres de son équipe de direction participeront à trois conférences dédiées aux investisseurs en septembre. ...
MaaT Pharma To Present and Participate in Investor and Medical Confere...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival of patients with cancer, announced that it will present two posters at the Society of Hematologic Oncology Annual Meeting taking place September 4-7, 2024, in Houston, Texas, USA. In addition, MaaT Pharma announced that Company management will participate in three investor conferences in September. Details are as follows: Society of Hematologic Oncology Annual Meeti...
- Thijs Berkelder
Alfen : New strategic plan takes longer than we hoped for
>Feedback analyst conference call - No new equity needed. CEO confirms Alfen does not expect it will need new capitalGuidance Q3 revenues per segment. Now guiding for EV Charging Q3 lower than Q2 (previously sequential rise) and stronger Q4, for Energy Storage Q3 similar as Q1 and stronger Q4 again, for Smart Grids a Q3 similar to Q2 and stronger Q4. Our view: impression of lower outlook for EV Charging and Smart Grids vs. higher in Energy Storage.Ramp-up su...
- ING Helpdesk
- Roy Külter
- Steven Boumans
- Roy Külter
- Steven Boumans
- Guy Sips
- Hilde Van Boxstael
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Alfen: H1 in line with updated guidance
Yesterday, Alfen published H1 2024 figures (EUR246m top line, 6% EBITDA margin) slightly above consensus expectations for EUR241m in revenue and 4% EBITDA margin. The numbers were in line with revised expectations for Q2 mostly impacted by moisture issues in Smart Grids (+9% YoY) and sluggish EV Ch
- Thijs Berkelder
Alfen : More clarity on new business plan, strategy, financing by end ...
>24H1 results better than consensus, but weaker than AAOB forecast - Revenue in 24H1 was up 10% y-o-y to € 245.7m (consensus € 239.6m) with- EV Charging revenue was up 1% y-o-y to € 80.1m (consensus € 78.4m), implying Q2 was € 40.8m, after Q1 of € 39.3m.- Smart Grid Solutions revenue grew by 9% y-o-y to € 93.5m (consensus € 99.0m), implying Q2 of € 38.6m after Q1 of € 54.9m.- Energy Storage Systems revenue up 23% y-o-y to € 72.2m (consensus € 62.2m), im...
- Thibault Leneeuw
Alfen Better than expected results, A move in the right direction
Alfen reported revenue growth of 10% y/y to € 246m well above expectations (KBCS: € 231m, CSS: 240m). Gross profit margin decreased from 30.5% in 1H23 to 28.9% in 1H24, after the expected one off costs gross profit margin was with 22.3% (KBCS: 25.3%, CSS: 24.1%) weaker than expected. However, adjusted EBITDA at € 13.5m significantly above our and CSS forecasts of € 12.2m. Furthermore, did they obtain a temporary waiver for 3Q24. A strategy update in 4Q24 can be expected which will be used for c...
- ING Helpdesk
- Usama Tariq
- Usama Tariq
- Thijs Berkelder
Alfen : Market awaiting clarity on waiver and reorganisation measures
>H1 results will be published on 21 August after trading hours - Alfen will report its H1 results on Wednesday 21 August at 18h CET, so after trading hours. An analyst conference call will be held on Thursday 22 August as from 9h CET hosted by CEO Marco Roeleveld, CFO a,i. Onno Krap, and CCO Michelle Lesh.Weakened guidance for 2024: On 26 June, Alfen downward adjusted its guidance for 2024 and said to assess its medium term growth ambitions in 24H2. It lowered it...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.